Novartis Vaccines & Diagnostics, Gmbh

Novartis Ag

Johanna M Jansen

Paul A Renhowe

Savithri Ramurthy

Keith Bruce Pfister

Cynthia Shafer

Christopher McBride

Allan S Wagman

Simon C Ng

Weibo Wang

Sabina Pecchi

Sharadha Subramanian

Paul Andrew Barsanti

Yasheen Zhou

Xiaodong Lin

Stephen David Harrison

Zhi-Jie Ni

Timothy D Machajewski

Rama Jain

Alice C Rico

Marion Wiesmann

Payman Amiri

Elisa Jazan

Robert L Warne

William R McCrea

Carla C Heise

Kelly Wayman

Mina E Aikawa

Jeffrey H Dove

Wei Shu

Dirksen Bussiere

Joel B Silver

Xiaojong M Wang

Jeremy M Murray

Stephen E Basham

The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions. 

Quinazolines for PDK1 inhibition

Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.

Indazole benzimidazole compounds

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. 

Benzimidazole quinolinones and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Johanna M Jansen